Phase 3 wins put Dermavant closer to filing Otezla rival tap...

Just two years after buying rights to psoriasis candidate tapinarof from GlaxoSmithKline, Swiss biotech Dermavant says it could be a few months away from filing for approval of

Roche begins phase 3 trial of Actemra in COVID-19 pneumonia

Roche is to begin a phase 3 trial of its Actemra/RoActemra as a treatment for patients hospitalised with severe COVID-19 pneumonia, following independent research in China suggesting it may

Sumitomo, Roivant close $3 billion deal, forming Sumitovant

Sumitomo and Roivant put flesh on bones of $3bn R&D deal

Sumitomo Dainippon bolts on pipeline via $3bn Roivant allian...

Roivant wins $200m backing to expand R&D operations

Biotech startup Roivant has won a further $200 million backing from investors in a financing round valuing the company at $7 billion.